Heartbeam (BEAT) Registration Filing summary

Company overview and business model

• Focuses on ambulatory cardiac monitoring with a proprietary 3D ECG platform enabling cable-free, high-fidelity 12-lead ECG readings outside healthcare facilities.

• Initial product, HeartBeam System, is FDA-cleared for arrhythmia assessment and features a portable, credit card-sized device, patient app, physician portal, and cloud-based algorithms.

• Growth strategy includes limited launch in early 2026, expansion into heart attack detection, development of an extended wear patch, and leveraging AI for predictive analytics.

• Holds 24 issued patents worldwide, with additional pending applications, supporting future product expansion into patches and smartwatch-based monitors.

• Targets concierge and preventive cardiology groups, with plans to expand to broader markets and partner with payors for reimbursement.

Financial performance and metrics

• As of December 31, 2025, had 40,117,404 shares of common stock outstanding and no preferred stock issued.

• 16 employees as of year-end 2025, increasing to 17 in January 2026 with the hiring of a Chief Commercial Officer.

• $78.8 million of previously registered securities remain unsold and are included in the current registration.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used as set forth in the applicable prospectus supplement.